A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 Administered Weekly in 4-weeks in Patients With Type 2 Diabetes Mellitus on Stable Metformin and Exenatide therapy.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 Administered Weekly in 4-weeks in Patients With Type 2 Diabetes Mellitus on Stable Metformin and Exenatide therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs RO 5095932 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top